PGEN
- Precigen, Inc.
()
Overview
Company Summary
Precigen, Inc. (PGEN) is a cutting-edge biotechnology company that specializes in leveraging synthetic biology and gene editing technologies to develop innovative solutions for various industries. With a focus on precision medicine and advanced therapies, Precigen aims to transform the way diseases are diagnosed, treated, and prevented.
The company operates through its two main business segments:
1. Therapeutics: Precigen's therapeutics segment is dedicated to developing next-generation gene and cell therapies to address unmet medical needs. They utilize their proprietary UltraVector� platform, which combines advanced gene transfer techniques with gene editing technologies like CRISPR-Cas9 to precisely modify and control gene expression. This segment primarily focuses on developing therapies for cancer, genetic disorders, autoimmune diseases, and rare diseases.
2. Food: Precigen's food segment is focused on developing agricultural biotechnology to enhance food production, quality, and sustainability. Through their subsidiary, Intrexon, the company employs genetic engineering and synthetic biology techniques to develop genetically modified organisms (GMOs), such as plants and animals, with improved traits. These traits include enhanced nutritional content, disease resistance, and increased crop yield, which can contribute to addressing global food security challenges.
As an innovative biotech company, Precigen collaborates with strategic partners, including academic institutions, pharmaceutical companies, and agricultural companies, to advance their research and development efforts. They also pursue strategic alliances and licensing agreements to commercialize their technologies and bring their products to market.
Overall, Precigen, Inc. is dedicated to pushing the boundaries of biotechnology through their efforts in precision medicine and advanced therapies, as well as their contributions to agricultural biotechnology.